Cargando…

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction

AIM: Recent data suggest that guideline‐directed medical therapy of patients with heart failure (HF) with reduced ejection fraction (HFrEF) might improve clinical outcomes in patients with HF up to a left ventricular ejection fraction (LVEF) of 55–65%, whereas patients with higher LVEF do not seem t...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Essen, Bart J., Tromp, Jasper, ter Maaten, Jozine M., Greenberg, Barry H., Gimpelewicz, Claudio, Felker, G. Michael, Davison, Beth A., Severin, Thomas, Pang, Peter S., Cotter, Gad, Teerlink, John R., Metra, Marco, Voors, Adriaan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Acute Heart Failure
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092799/ https://www.ncbi.nlm.nih.gov/pubmed/36114655 http://dx.doi.org/10.1002/ejhf.2695

Ejemplares similares

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Association of time‐to‐intravenous furosemide with mortality in acute heart failure: data from REPORT‐HF
por: Ouwerkerk, Wouter, et al.
Publicado: (2022)

Worsening renal function in acute heart failure in the context of diuretic response
por: Emmens, Johanna E., et al.
Publicado: (2021)

Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
por: Biegus, Jan, et al.
Publicado: (2019)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

Morphine in the Setting of Acute Heart Failure: Do the Risks Outweigh the Benefits?
por: Caspi, Oren, et al.
Publicado: (2020)

Temporary Mechanical Circulatory Support in Acute Heart Failure
por: Jiritano, Federica, et al.
Publicado: (2020)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failure
por: Mondritzki, Thomas, et al.
Publicado: (2020)

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
por: Putri, Desak Ketut Sekar Cempaka, et al.
Publicado: (2023)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Vasodilators in the treatment of acute heart failure: what we know, what we don’t
por: Metra, Marco, et al.
Publicado: (2008)

Additive value of dobutamine stress echocardiography in patients with an anomalous origin of a coronary artery
por: Lameijer, Heleen, et al.
Publicado: (2015)

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
por: Voors, Adriaan A, et al.
Publicado: (2014)

Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study
por: Meyer, Sven, et al.
Publicado: (2016)

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
por: Metra, Marco, et al.
Publicado: (2010)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
por: Njoroge, Joyce N., et al.
Publicado: (2021)

Refractory Recurrent Pericarditis After Pericardiectomy in a Young Woman
por: Lak, Hassan Mehmood, et al.
Publicado: (2021)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

The New Heart Failure Association Definition of Advanced Heart Failure
por: Metra, Marco, et al.
Publicado: (2019)

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Association of early versus delayed normalisation of left ventricular ejection fraction with mortality in ischemic cardiomyopathy
por: Schiffer, Walter B, et al.
Publicado: (2021)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Implantation of a vagus nerve stimulator for patients with heart failure with reduced ejection fraction: An educational video
por: Al Rameni, Dina, et al.
Publicado: (2022)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ehl08kjgt0inrev1guk9g7acus